Yongsik Cho

Yongsik Cho

Auto-generated profile, based on publicly available information

Yongsik Cho

Liflex Science, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
YCYongsik Cho
Yongsik Cho
SJSumin Jeong
Sumin Jeong
HKHyeonkyeong Kim
Hyeonkyeong Kim
DKDonghyun Kang
Donghyun Kang
JLJeeyeon Lee
Jeeyeon Lee
JKJin-Hong Kim
Jin-Hong Kim
Osteoarthritis (OA) is the most common form of arthritis. It is characterized by progressive destruction of articular cartilage and the development of chronic pain and constitutes a considerable socioeconomic burden. Currently, pharmacological treatments mostly aim to relieve the OA symptoms associated with inflammation and pain. However, with increasing understanding of OA pathology, several potential therapeutic targets have been identified, enabling the development of disease-modifying OA drugs (DMOADs). By targeting inflammatory cytokines, matrix-degrading enzymes, the Wnt pathway, and OA-associated pain, DMOADs successfully modulate the degenerative changes in osteoarthritic cartilage. Moreover, regenerative approaches aim to counterbalance the loss of cartilage matrix by stimulating chondrogenesis in endogenous stem cells and matrix anabolism in chondrocytes. Emerging strategies include the development of senolytic drugs or RNA therapeutics to eliminate the cellular or molecular sources of factors driving OA. This review describes the current developmental status of DMOADs and the corresponding results from preclinical and clinical trials and discusses the potential of emerging therapeutic approaches to treat OA.

19 November 2021 in Science Advances
Verified
Journal Article
Open access
YCYongsik Cho
Yongsik Cho
HKHyeon-Seop Kim
Hyeon-Seop Kim
DKDonghyun Kang
Donghyun Kang
HKHyeonkyeong Kim
Hyeonkyeong Kim
NLNarae Lee
Narae Lee
JKJin-Hong Kim
Jin-Hong Kim
Neutralization of CTRP3 opposes degenerative tendon matrix remodeling during tendinopathy.

1 May 2012 in Journal of Hydro-environment Research
Verified
Journal Article
Closed access
WJWoochang Jeong
Woochang Jeong
JYJae-Seon Yoon
Jae-Seon Yoon
YCYong-Sik Cho
Yong-Sik Cho

4 March 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
YCYongsik Cho
Yongsik Cho
HKHyeonkyeong Kim
Hyeonkyeong Kim
GYGeunho Yook
Geunho Yook
SYSangmin Yong
Sangmin Yong
SKSoy Kim
Soy Kim
JKJin-Hong Kim
Jin-Hong Kim
Objective: Interferon regulatory factor 1 (IRF1) is a transcriptional regulator conventionally associated with immunomodulation. Recent molecular analyses mapping DNA binding sites of IRF1 have suggested its potential function in DNA repair. However, the physiologic significance of this noncanonical function remains unexplored. Here, we investigated the role of IRF1 in osteoarthritis (OA), a condition marked by senescence and chronic joint inflammation.Methods: OA progression was examined in wild‐type and Irf1−/− mice using histologic assessments and microcomputed tomography analysis of whole‐joint OA manifestations and behavioral assessments of joint pain. An integrated analysis of assay for transposase‐accessible chromatin with sequencing and whole transcriptome data was conducted for the functional assessment of IRF1 in chondrocytes. The role of IRF1 in DNA repair and senescence was investigated by assaying γ‐H2AX foci and senescence‐associated beta‐galactosidase activity.Results: Our genome‐wide investigation of IRF1 footprinting in chondrocytes revealed its primary occupancies in the promoters of DNA repair genes without noticeable footprint patterns in those of interferon‐responsive genes. Chondrocytes lacking IRF1 accumulated irreversible DNA damage under oxidative stress, facilitating their entry into cellular senescence. IRF1 was down‐regulated in the cartilage of human and mouse OA. Although IRF1 overexpression did not elicit an inflammatory response in joints or affect OA development, genetic deletion of Irf1 caused enhanced chondrocyte senescence and exacerbated post‐traumatic OA in mice.Conclusion: IRF1 offers DNA damage surveillance in chondrocytes, protecting them from oxidative stress associated with OA risk factors. Our study provides a crucial and cautionary perspective that compromising IRF1 activity renders chondrocytes vulnerable to cellular senescence and promotes OA development. image

30 December 2011 in Korean Journal of Crop Science
Verified
Journal Article
Open access
KCKyung-Jin Choi
Kyung-Jin Choi
TPTae-Shik Park
Tae-Shik Park
CLChoon-Ki Lee
Choon-Ki Lee
KHKi-Yong Ha
Ki-Yong Ha
WYWoon-Ho Yang
Woon-Ho Yang
HKHang-Won Kang
Hang-Won Kang

1 September 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
HOHye-Kyoung Oh
Hye-Kyoung Oh
MPMinsun Park
Minsun Park
SCSeung-Won Choi
Seung-Won Choi
DJDa-Un Jeong
Da-Un Jeong
BKByoung Ju Kim
Byoung Ju Kim
DKDae-Won Kim
Dae-Won Kim
Osteoarthritis (OA) is an incurable joint disease affecting 240 million elderly population, and major unmet medical needs exist for better therapeutic options for OA. During skeletal development, Nkx3.2 has been shown to promote chondrocyte differentiation and survival, but to suppress cartilage hypertrophy and blood vessel invasion. Here we show that Nkx3.2 plays a key role in osteoarthritis (OA) pathogenesis. Marked reduction of Nkx3.2 expression was observed in three different murine OA models. Consistent with these findings, analyses of surgery-induced and age-driven OA models revealed that cartilage-specific post-natal induction of Nkx3.2 can suppress OA progression in mice. These results suggest that Nkx3.2 may serve as a promising target for OA drug development.